The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis

Aroon D Hingorani; Juan Pablo Casas; Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium; Jackie Price; Marlene Stewart; Malcolm Dunlop; Ian Tomlinson

doi:10.1016/S0140-6736(12)60110-X

The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis

Aroon D Hingorani, Juan Pablo Casas, Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium, Jackie Price, Marlene Stewart, Malcolm Dunlop, Ian Tomlinson

Research output: Contribution to journal › Article › peer-review

Abstract / Description of output

A high circulating concentration of interleukin 6 is associated with increased risk of coronary heart disease. Blockade of the interleukin-6 receptor (IL6R) with a monoclonal antibody (tocilizumab) licensed for treatment of rheumatoid arthritis reduces systemic and articular inflammation. However, whether IL6R blockade also reduces risk of coronary heart disease is unknown.

Original language	English
Pages (from-to)	1214-24
Number of pages	11
Journal	The Lancet
Volume	379
Issue number	9822
DOIs	https://doi.org/10.1016/S0140-6736(12)60110-X
Publication status	Published - 2012

Access to Document

10.1016/S0140-6736(12)60110-X

The interleukin-6 receptor as a target for prevention of coronary heart disease a mendelian randomisation analysisFinal published version, 306 KB

http://www.sciencedirect.com/science/article/pii/S014067361260110X

Cite this

@article{a77c4515d18e418d9fb9288762ef7a79,

title = "The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis",

abstract = "A high circulating concentration of interleukin 6 is associated with increased risk of coronary heart disease. Blockade of the interleukin-6 receptor (IL6R) with a monoclonal antibody (tocilizumab) licensed for treatment of rheumatoid arthritis reduces systemic and articular inflammation. However, whether IL6R blockade also reduces risk of coronary heart disease is unknown.",

author = "Hingorani, {Aroon D} and Casas, {Juan Pablo} and {Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium} and Jackie Price and Marlene Stewart and Malcolm Dunlop and Ian Tomlinson",

year = "2012",

doi = "10.1016/S0140-6736(12)60110-X",

language = "English",

volume = "379",

pages = "1214--24",

journal = "The Lancet",

issn = "1474-547X",

publisher = "Elsevier",

number = "9822",

}

TY - JOUR

T1 - The interleukin-6 receptor as a target for prevention of coronary heart disease

T2 - a mendelian randomisation analysis

AU - Hingorani, Aroon D

AU - Casas, Juan Pablo

AU - Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium

AU - Price, Jackie

AU - Stewart, Marlene

AU - Dunlop, Malcolm

AU - Tomlinson, Ian

PY - 2012

Y1 - 2012

N2 - A high circulating concentration of interleukin 6 is associated with increased risk of coronary heart disease. Blockade of the interleukin-6 receptor (IL6R) with a monoclonal antibody (tocilizumab) licensed for treatment of rheumatoid arthritis reduces systemic and articular inflammation. However, whether IL6R blockade also reduces risk of coronary heart disease is unknown.

AB - A high circulating concentration of interleukin 6 is associated with increased risk of coronary heart disease. Blockade of the interleukin-6 receptor (IL6R) with a monoclonal antibody (tocilizumab) licensed for treatment of rheumatoid arthritis reduces systemic and articular inflammation. However, whether IL6R blockade also reduces risk of coronary heart disease is unknown.

U2 - 10.1016/S0140-6736(12)60110-X

DO - 10.1016/S0140-6736(12)60110-X

M3 - Article

C2 - 22421340

SN - 1474-547X

VL - 379

SP - 1214

EP - 1224

JO - The Lancet

JF - The Lancet

IS - 9822

ER -

The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis

Abstract / Description of output

Access to Document

Fingerprint

Cite this